75A50126C00005↗
Isola Therapeutics Inc received this contract from Barda - Aspr / Daappo / Barda Dcma, Office of Assistant Secretary for Preparedness and Response: $7.49M obligated so far for health r&d services; health care services; experimental development. It runs to 2028-10-31.
Key facts · data as of Oct 25, 2026
- Recipient
- Isola Therapeutics Inc
- Awarding agency
- Office of Assistant Secretary for Preparedness and Response (Department of Health and Human Services)
- Contracting office
- Barda - Aspr / Daappo / Barda Dcma (75A501)
- Obligated to date
- $7.49M
- Potential value
- $7.49M
- Ends
- 2028-10-31
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 25, 2026.
Cite this page: SpendQuery, Award 75A50126C00005, data as of Oct 25, 2026, https://spendquery.com/award?id=CONT_AWD_75A50126C00005_7505_-NONE-_-NONE-
Isola Therapeutics Inc: all federal awards · Department of Health and Human Services: spending · Barda - Aspr / Daappo / Barda Dcma: what it buys
THE PURPOSE OF THIS AWARD IS TO ADVANCE THE DEVELOPMENT OF ISOLA'S NEBULIZATION THERAPY, A MEDICAL COUNTERMEASURE DESIGNED TO PREVENT AND TREAT PULMONARY FOAM THE INHALATION OF CHEMICAL AGENTS CAUSES.
What it is
- Product or service
- Health R&D Services; Health Care Services; Experimental Development (PSC AN13)
- Industry
- Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) (NAICS 541715)
- Contracting office
- Barda - Aspr / Daappo / Barda Dcma (75A501)
- Competition
- Full and open competition · 1 offer received
- Pricing
- Firm fixed price
- How it was bought
- Standalone contract
- Solicitation
- EZ-BAA-22-100-SOL-00003
- Where the work is
- Hennepin, MN · district MN-05
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
1 action since 2026-04-27. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-04-27 | 0 | $7.49M | THE PURPOSE OF THIS AWARD IS TO ADVANCE THE DEVELOPMENT OF ISOLA'S NEBULIZATION THERAPY, A MEDICAL COUNTERMEASURE DESIGNED TO PREVENT AND TREAT PULMONARY FOAM THE INHALATION OF CHEMICAL AGENTS CAUSES. |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-25). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗